

Tuberculosis profile: Rwanda

Population 2019: 13 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	7 200 (5 500-9 100)	57 (44-72)
HIV-positive TB incidence	1 500 (1 200-1 900)	12 (9.2-15)
MDR/RR-TB incidence**	190 (130-260)	1.5 (1.1-2.1)
HIV-negative TB mortality	620 (400-900)	4.9 (3.2-7.1)
HIV-positive TB mortality	320 (220-430)	2.5 (1.8-3.4)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	2.2% (1.7-2.7)
Previously treated cases	7.1% (4.7-10)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	80% (63-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	13% (9-19)

TB case notifications, 2019

Total new and relapse	5 766
- % tested with rapid diagnostics at time of diagnosis	58%
- % with known HIV status	100%
- % pulmonary	84%
- % bacteriologically confirmed ^	85%
- % children aged 0-14 years	7%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	28%
- % men	65%
Total cases notified	5 892

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	1 178	20%
- on antiretroviral therapy	1 065	90%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	92%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	89%
Laboratory-confirmed cases - MDR/RR-TB ^^	101
Patients started on treatment - MDR/RR-TB ^^^	100
Laboratory-confirmed cases - XDR-TB ^^	0
Patients started on treatment - XDR-TB ^^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	88

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	86%	5 750
Previously treated cases, excluding relapse, registered in 2018	83%	127
HIV-positive TB cases registered in 2018	78%	1 174
MDR/RR-TB cases started on second-line treatment in 2017	81%	77
XDR-TB cases started on second-line treatment in 2017		0

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	59% (54-64)
---	----------------

TB financing

National TB budget, 2020 (US\$ millions)	8
- Funding source, domestic	15%
- Funding source, international	85%
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)